Low FEV1 Is Associated With Increased Risk Of Cachexia In COPD Patients

References

• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP22878278
   PubMed Web of Science ®Google Scholar
• López‐Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. doi:10.1111/resp.1266026494423
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• Wagner P. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008;31(3):492–501. doi:10.1183/09031936.0007480718310396
   PubMed Web of Science ®Google Scholar
• Mokari-Yamchi A, Sharifi A, Kheirouri S. Increased serum levels of S100A1, ZAG, and adiponectin in cachectic patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3157.30349224
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418–1422.9603117
   PubMed Web of Science ®Google Scholar
• Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41(41 suppl):46s–53s.12795331
   PubMedGoogle Scholar
• Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun. 1965;19(6):739–744.4953930
   PubMed Web of Science ®Google Scholar
• Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X. S100 proteins as an important regulator of macrophage inflammation. Front Immunol. 2018;8:1908.29379499
   PubMed Web of Science ®Google Scholar
• Zimmer DB, Landar A. Analysis of S100A1 expression during skeletal muscle and neuronal cell differentiation. J Neurochem. 1995;64(6):2727–2736. doi:10.1046/j.1471-4159.1995.64062727.x7760053
   PubMed Web of Science ®Google Scholar
• Lagasse E, Weissman I. Mouse MRP8 and MRP14, two intracellular calcium-binding proteins associated with the development of the myeloid lineage. Blood. 1992;79(8):1907–1915.1373330
   PubMed Web of Science ®Google Scholar
• Cabassi A, Tedeschi S. Zinc-α2-glycoprotein as a marker of fat catabolism in humans. Curr Opin Clin Nutr Metab Care. 2013;16(3):267–271. doi:10.1097/MCO.0b013e32835f816c23448999
   PubMed Web of Science ®Google Scholar
• Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004;50(9):1511–1525. doi:10.1373/clinchem.2004.03248215265818
   PubMed Web of Science ®Google Scholar
• Uzum AK, Aydin MM, Tutuncu Y, Omer B, Kiyan E, Alagol F. Serum ghrelin and adiponectin levels are increased but serum leptin level is unchanged in low weight chronic obstructive pulmonary disease patients. Eur J Intern Med. 2014;25(4):364–369. doi:10.1016/j.ejim.2013.02.01223523152
   PubMed Web of Science ®Google Scholar
• Kırdar S, Serter M, Ceylan E, Şener AG, Kavak T, Karadağ F. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest. 2009;69(2):219–224. doi:10.1080/0036551080247440018946779
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. doi:10.1164/rccm.200703-456SO17507545
   PubMed Web of Science ®Google Scholar
• Crapo RO, Hankinson JL, Irvin C, et al. Standardization of spirometry: 1994 update. Am J. Respir Crit Care Med. 1995;152(3):1107–1136. doi:10.1164/ajrccm.152.3.7663792
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Blundell J, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes. 2000;24(1):38. doi:10.1038/sj.ijo.0801083
   PubMed Web of Science ®Google Scholar
• Vasheghani-Farahani A, Tahmasbi M, Asheri H, Ashraf H, Nedjat S, Kordi R. The Persian, last 7-day, long form of the International Physical Activity Questionnaire: translation and validation study. Asian J Sports Med. 2011;2(2):106. doi:10.5812/asjsm22375226
   PubMedGoogle Scholar
• Jones RL, Nzekwu -M-MU. The effects of body mass index on lung volumes. Chest. 2006;130(3):827–833. doi:10.1378/chest.130.3.82716963682
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Lareau SC, Meek PM. Predictors of survival in COPD: more than just the FEV1. Respir Med. 2008;102:S27–S35. doi:10.1016/S0954-6111(08)70005-218582794
   PubMed Web of Science ®Google Scholar
• De S. Body mass index among patient with chronic obstructive pulmonary diseases. Indian J Physiol Pharmacol. 2012;56(4):353–358.23781655
   PubMedGoogle Scholar
• Gologanu D, Ionita D, Gartonea T, Stanescu C, MA B. Body composition in patients with chronic obstructive pulmonary disease. Maedica. 2014;9(1):25.25553122
   PubMedGoogle Scholar
• Wu Z, Yang D, Ge Z, Yan M, Wu N, Liu Y. Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: a retrospective real world research. J Thorac Dis. 2018;10(8):5086. doi:10.21037/jtd.2018.08.6730233884
   PubMed Web of Science ®Google Scholar
• Creutzberg E, Schols A, Bothmer-Quaedvlieg F, Wouters E. Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr. 1998;52(6):396. doi:10.1038/sj.ejcn.16005719683390
   PubMed Web of Science ®Google Scholar
• Brúsik M, Ukropec J, Joppa P, et al. Circulatory and adipose tissue leptin and adiponectin in relationship to resting energy expenditure in patients with chronic obstructive pulmonary disease. Physiol Res. 2012;61(5):469–480.22881231
   PubMed Web of Science ®Google Scholar
• Hill K, Vogiatzis I, Burtin C. The importance of components of pulmonary rehabilitation, other than exercise training, in COPD. Eur Respiratory Soc. 2013;22:405–413. doi:10.1183/09059180.00002913
   Google Scholar
• van der Molen T. Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequences. Prim Care Respir J. 2010;19(4):326. doi:10.4104/pcrj.2010.0005320842323
   PubMedGoogle Scholar
• Sanders KJ, Kneppers AE, van de Bool C, Langen RC, Schols AM. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. J Cachexia Sarcopenia Muscle. 2016;7(1):5–22.27066314
   PubMed Web of Science ®Google Scholar
• Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–919.15867843
   PubMed Web of Science ®Google Scholar
• Chan KH, Yeung SC, Yao TJ, et al. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2010;14(9):1193–1200.20819268
   PubMed Web of Science ®Google Scholar
• Yoon HI, Li Y, Man SP, et al. The complex relationship of serum adiponectin to COPD outcomes. Chest. 2012;142(4):893–899.22207678
   PubMed Web of Science ®Google Scholar
• Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P. Zinc‐α2‐glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett. 2005;579(1):41–47.15620688
   PubMed Web of Science ®Google Scholar
• Mracek T, Ding Q, Tzanavari T, et al. The adipokine zinc‐α2‐glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. Clin Endocrinol. 2010;72(3):334–341.
   Web of Science ®Google Scholar
• Marrades M, Martinez J, Moreno-Aliaga M. ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. J Physiol Biochem. 2008;64(1):61–66.18663996
   PubMed Web of Science ®Google Scholar
• Schneider M, Hansen JL, Sheikh SP. S100A4: a common mediator of epithelial–mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med. 2008;86(5):507–522.18322670
   PubMed Web of Science ®Google Scholar
• Wang T, Huo X, Chong Z, Khan H, Liu R. A review of S100 protein family in lung cancer. Clinica Chimica Acta. 2018;476:54–59.
   PubMed Web of Science ®Google Scholar
• Prosser BL, Wright NT, Hernãndez-Ochoa EO, et al. S100A1 binds to the calmodulin-binding site of ryanodine receptor and modulates skeletal muscle excitation-contraction coupling. JBC. 2008;283(8):5046–5057.
   PubMed Web of Science ®Google Scholar
• Cannon BR, Zimmer DB, Weber DJ. S100A1 (S100 calcium binding protein A1). Atlas Genet Cytogenet Oncol Haematol. 2011;15(10):873–876.26213580
   PubMedGoogle Scholar
• Pleger ST, Harris DM, Shan C, et al. Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res. 2008;102(7):786–794.18292599
   PubMed Web of Science ®Google Scholar